Dashboard
Manage Tickers

AIM AIM ImmunoTech Inc.

NYSE aimimmuno.com


$ 2.65 $ 0.02 (0.78 %)    

Monday, 20-Oct-2025 18:50:35 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 2.59
$ 2.62
$ 2.51 x 100
$ 2.69 x 49
$ 2.56 - $ 2.68
$ 0.06 - $ 20.35
69,031
na
7.02M
$ -1.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-30-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 03-30-2018 12-31-2017 10-K
32 11-14-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-16-2016 03-31-2016 10-Q
39 03-29-2016 12-31-2015 10-K
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ascendiant-capital-maintains-buy-on-aim-immunotech-lowers-price-target-to-24
Ascendiant Capital Maintains Buy on AIM Im...
10/03/2025 10:19:56

Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $150 t...

aim-immunotech-secures-japanese-patent-for-ampligen-in-combination-with-checkpoint-inhibitors-for-the-treatment-of-cancer
AIM ImmunoTech Secures Japanese Patent For...
09/25/2025 12:46:47

aim-immunotech-has-been-granted-european-patent-number-ep4096675-titled-compositions-for-treating-long-covid
AIM ImmunoTech Has Been Granted European P...
09/22/2025 19:58:47

https://register.epo.org/application?number=EP21818146

aim-immunotech-says-jitc-publishes-new-peer-reviewed-article-providing-evidence-of-combination-effect-of-aims-drug-ampligen-and-interferon-alpha-on-tumor-growth-and-subsequent-subject-survival
AIM ImmunoTech Says JITC Publishes New Pee...
09/22/2025 13:05:11

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Journal for ImmunoTherapy of C...

aim-immunotech-q2-eps-368-beats-800-estimate-sales-2500k-miss-10000k-estimate
AIM ImmunoTech Q2 EPS $(3.68) Beats $(8.00...
08/15/2025 13:11:57

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(3.68) per share which beat the analyst consensus estimate of $(8.00) b...

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

uncovering-potential-aim-immunotechs-earnings-preview
Uncovering Potential: AIM ImmunoTech's Ear...
08/13/2025 16:01:47

aim-immunotech-announces-that-its-drug-ampligen-will-be-featured-in-four-presentations-at-upcoming-5th-annual-marie-sklodowska-curie-symposium-on-cancer-research-and-care-in-warsaw-poland
Aim Immunotech Announces That Its Drug Amp...
08/06/2025 13:04:59

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the strong clinical successes in o...

aim-immunotech-announces-company-update-including-mid-year-report-of-ampligen-in-combination-with-astrazenecas-imfinzi-for-treatment-of-pancreatic-cancer-demonstrating-signs-of-both-no-significant-toxicity-and-superior-pfs-and-oscompany-also-bolstered-cash-position-to-fund-operations-for-12-months
AIM ImmunoTech Announces Company Update In...
08/04/2025 13:06:24

Primary focus on pancreatic cancerMid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (d...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/29/2025 17:06:19

crude-oil-gains-over-1-unitedhealth-earnings-miss-views
Crude Oil Gains Over 1%; UnitedHealth Earn...
07/29/2025 16:53:28

us-stocks-mixed-procter--gamble-posts-upbeat-earnings
US Stocks Mixed; Procter & Gamble Posts Up...
07/29/2025 14:13:18

aim-immunotech-announces-pricing-of-2m-shares-class-e-warrants-and-class-f-warrants-at-combined-public-offering-price-gross-proceeds-8m
AIM ImmunoTech Announces Pricing Of 2M Sha...
07/29/2025 13:01:57

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/29/2025 12:07:53

why-celestica-shares-are-trading-higher-by-around-12-here-are-20-stocks-moving-premarket
Why Celestica Shares Are Trading Higher By...
07/29/2025 10:46:00

crude-oil-gains-2-cea-industries-shares-spike-higher
Crude Oil Gains 2%; CEA Industries Shares ...
07/28/2025 16:05:27

why-is-micro-cap-aim-immunotech-stock-surging
Why Is Micro-Cap AIM ImmunoTech Stock Surg...
07/28/2025 15:12:25

AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.

us-stocks-mixed-enterprise-products-partners-posts-upbeat-earnings
US Stocks Mixed; Enterprise Products Partn...
07/28/2025 14:03:41

aim-immunotech-announces-mid-year-data-from-phase-2-duripanc-trial-of-ampligen-and-astrazenecas-imfinzi-in-metastatic-pancreatic-cancer-patients-post-folfirinox
AIM ImmunoTech Announces Mid-Year Data Fro...
07/28/2025 13:03:41

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive data in a mid-year update from ...

aim-immunotech-receives-nyse-notification-regarding-noncompliance-with-minimum-stockholders-equity-requirements
AIM ImmunoTech Receives NYSE Notification ...
06/20/2025 20:17:38

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION